Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott has announced that the FDA approved the Xience V everolimus eluting coronary stent system for the treatment of coronary artery disease.
Subscribe to our email newsletter
The Xience V drug coated stent is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure.
Abbott’s Xience V is said to be the only drug eluting stent to have demonstrated superiority over Boston Scientific’s Taxus paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. Xience V will be launched in the US immediately.
John Capek, executive vice president of medical devices at Abbott, said: “Xience V represents an important treatment advance for the estimated 13 million people in the US suffering from coronary artery disease, and we believe Xience V will quickly become the new standard for drug eluting stents given its outstanding clinical results.”